Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
4basebio UK Societas ( (GB:4BB) ) has issued an announcement.
4basebio PLC announced that RBC Capital Markets has initiated research coverage on the company, highlighting its innovative approach in the biotechnology sector. This development is significant as it may enhance the company’s visibility and credibility in the market, potentially attracting more investors and stakeholders interested in its synthetic DNA products and nucleic acid delivery platforms.
More about 4basebio UK Societas
4basebio (AIM: 4BB) is an innovation-driven biotechnology company focused on the development of advanced therapy medicinal products (ATMPs). It specializes in high-performance synthetic DNA products and a non-viral, cell-targeting nucleic acid delivery platform. The company aims to lead the market in manufacturing and supplying high-quality synthetic DNA products for research, therapeutic, and pharmacological use, as well as developing target-specific non-viral vectors for efficient payload delivery in patients.
YTD Price Performance: -7.85%
Average Trading Volume: 763
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £172.7M
Learn more about 4BB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue